Hotline:400-820-3792Inhibitors?Agonists?ScreeningLibrarieswww.MedChemEHydrocortisoneCat.No.:HY-N0583CASNo.:50-23-7分?式:C??H??O?分?量:362.46作?靶點:GlucocorticoidReceptor;EndogenousMetabolite作?通路:GPCR/GProtein;MetabolicEnzyme/Protease儲存?式:4°C,protectfromlight*Insolvent:-80°C,6months;-20°C,1month(protectfromlight)溶解性數(shù)據(jù)體外實驗DMSO:≥31mg/mL(85.53mM)掃描?維碼，H2O:1.2mg/mL(3.31mM;Needultrasonic)運(yùn)?溶解?案計算器*"≥"meanssoluble,butsaturationunknown.獲得適合您實驗體系的溶解?案MassSolvent1mg5mg10mgConcentration制備儲備液1mM2.7589mL13.7946mL27.5893mL5mM0.5518mL2.7589mL5.5179mL10mM0.2759mL1.3795mL2.7589mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液，并請注意儲備液的保存?式和期限。體內(nèi)實驗請根據(jù)您的實驗動物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請先按照InVitro?式配制澄的儲備液，再依次添加助溶劑：為保證實驗結(jié)果的可靠性，澄的儲備液可以根據(jù)儲存條件，適當(dāng)保存；體內(nèi)實驗的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶1.請依序添加每種溶劑：1%DMSO99%saline2.Solubility:≥0.5mg/mL(1.38mM);Clearsolution請依序添加每種溶劑：10%DMSO40%PEG3005%Tween-8045%salineSolubility:≥2.5mg/mL(6.90mM);Clearsolution此?案可獲得≥2.5mg/mL(6.90mM，飽和度未知)的澄溶液。1/3www.MedChemEwww.MedChemE以1mL?作液為例，取100μL25.0mg/mL的澄DMSO儲備液加到400μLPEG300中，混合均勻；向上述3.體系中加?50μLTween-80，混合均勻；然后繼續(xù)加?450μL?理鹽?定容?1mL。請依序添加每種溶劑：10%DMSO90%(20%SBE-β-CDinsaline)Solubility:≥2.5mg/mL(6.90mM);Clearsolution此?案可獲得≥2.5mg/mL(6.90mM，飽和度未知)的澄溶液。以1mL?作液為例，取100μL25.0mg/mL的澄DMSO儲備液加到900μL20%的SBE-β-CD?理鹽??溶4.液中，混合均勻。請依序添加每種溶劑：10%DMSO90%cornoilSolubility:≥2.5mg/mL(6.90mM);Clearsolution此?案可獲得≥2.5mg/mL(6.90mM，飽和度未知)的澄溶液，此?案不適?于實驗周期在半個?以上的實驗。5.以1mL?作液為例，取100μL25.0mg/mL的澄DMSO儲備液加到900μL??油中，混合均勻。請依序添加每種溶劑：5%DMSO40%PEG3005%Tween-8050%saline6.Solubility:≥2.5mg/mL(6.90mM);Clearsolution請依序添加每種溶劑：5%DMSO95%(20%SBE-β-CDinsaline)Solubility:≥2.5mg/mL(6.90mM);ClearsolutionBIOLOGICALACTIVITY?物活性Hydrocortisone(Cortisol)腎上腺?質(zhì)分泌的類醇激素或糖?質(zhì)激素[1]。IC50&TargetHumanEndogenousMetabolite體外研究Hydrocortisone(50nM)showsadose-dependentdown-regulationofGRtranscriptinhCMEC/D3cells.Hydrocortisonesupplementationoftheserum-reducedcelldifferentiationmediumleadstoasignificantincreaseinTERacrossthehCMEC/D3monolayer[1].Hydrocortisone-treatedDendriticcells(DCs)showadecreasedexpressionofMHCIImolecules,thecostimulatorymoleculeCD86,andtheDC-specificmarkerCD83,aswellasastronglyreducedIL-12secretion.Hydrocortisone-treatedDCsinhibitproductionofIFN-γbutinduceanincreasedreleaseofIL-4andnochangeinIL-5[2].Hydrocortisonereducespostischemicoxidativestress,perfusionpressure,andtransudateformation.Hydrocortisoneinhibitspostischemicsheddingofsyndecan-1,heparansulfate,andhyaluronanasisreleaseofhistaminefromresidentmastcells[3].PROTOCOLCellAssay[1]CellsareplatedontopofcollagenIV-coatedtranswellchambersforsix-wellplates(24mmdiameter,membranematerial:polyethyleneterephthalate(PET),0.4μmpores,poredensity1.6×106cm2)atdensitiesof2.5×104cellscm2perwell.Whentheyhavereachedconfluenceatday5,thedifferentexperimentalsetsofcellsaretransferredtodifferentiationmediumcontainingreducedamountsofFCSandtreatedwithTNFαorhydrocortisoneasindicated.MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.戶使?本產(chǎn)品發(fā)表的科研?獻(xiàn)2/3www.MedChemEwww.MedChemE?Nature.2021Jan;589(7843):620-626.?ExpCellRes.2020Aug1;393(1):112054.?CancerManagRes.2019Jun21;11:5557-5572.?Funda??oOswaldoCruz.InstitutoOswaldoCruz.LaboratóriodeTransmissoresdeHematozoários.2020Sep.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].F?rsterC,etal.DifferentialeffectsofhydrocortisoneandTNFalphaontightjunctionproteinsinaninvitromodelofthehumanblood-brainbarrier.JPhysiol.2008Apr1;586(7):1937-49.[2].BellinghausenI,etal.InhibitionofhumanallergicT-cellresponsesbyIL-10-treateddendriticcells:differencesfromhydrocortisone-treateddendriticcells.JAllergyClinImmunol.2001Aug;108(2):242-9.[3].ChappellD,etal.Hydrocortisonepreservesthevascularbarrierbyprotectingtheendothelialglycocalyx.Anesthesiology.2007Nov;107(5):776-84.McePdfHeight關(guān)注MCE中國公眾號，

獲取前沿資訊、最新活動和

實?科研?具M(jìn)edChemExpre